Danone Expands Its Intestinal Health Focus With Acquisition of The Akkermansia Company

Danone has announced its acquisition of The Akkermansia Company, a Belgium-based pioneer in biotics that has nearly two decades of scientific expertise. TAC is known for discovering the biotic strain Akkermansia muciniphila MucT in 2004, which has been clinically proven to enhance intestinal barriers, reduce inflammation, and combat metabolic disorders such as obesity, diabetes, and cardiovascular diseases. This acquisition aligns with Danone's Renew strategy, aimed at accelerating its commitment to science and innovation amid growing consumer interest in health-enhancing products. Danone, a leader in the food industry, operates in high-growth categories and strives to inspire healthier and more sustainable consumption practices. With over 90,000 employees and product reach in more than 120 countries, Danone posted a turnover of 27.4 billion euros in 2024. Its portfolio includes renowned international and regional brands, and the company is listed on Euronext Paris. The communication further details forward-looking statements indicating future innovation and business directions, underlining various risks and uncertainties.